The Research field is simply huge and it shouldn't be too difficult to get a good return from just one, IMHO:
"There are a number of cancers, (eg Multiple Myeloma) and clinical situations, where the therapy results in the patient being chronically immuno-suppressed. Having little or no ability to fight off infection, such patients invariably suffer badly from even the most innocuous of infections.
In the end, infection control often becomes the clinically limiting step in the management of such patients. The ability to rejuvenate the immune system by the safe, effective production of a new T Cell repertoire in such cancer patients would be, we believe, a major advance in modern medical practice".
Gerry
NAL Price at posting:
0.0¢ Sentiment: None Disclosure: Held
